TY - CHAP AU - Garami, András ED - Vámos, Zoltán TI - Termoneutralitás T2 - Súlyos baleseti agysérültek ellátása PB - Medicina Könyvkiadó CY - Budapest SN - 9789632269177 PY - 2024 SP - 172 EP - 173 PG - 2 UR - https://m2.mtmt.hu/api/publication/34823724 ID - 34823724 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Garami, András ED - Vámos, Zoltán TI - Hőszabályozás T2 - Súlyos baleseti agysérültek ellátása PB - Medicina Könyvkiadó CY - Budapest SN - 9789632269177 PY - 2024 SP - 51 EP - 54 PG - 1 UR - https://m2.mtmt.hu/api/publication/34823695 ID - 34823695 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Rumbus, Zoltán AU - Fekete, Kata AU - Kelava, Leonardo AU - Gardos, Bibor AU - Klonfar, Krisztian AU - Kéringer, Patrik AU - Pintér, Erika AU - Pákai, Eszter AU - Garami, András TI - Ammonium chloride-induced hypothermia is attenuated by transient receptor potential channel vanilloid-1, but augmented by ankyrin-1 in rodents JF - LIFE SCIENCES J2 - LIFE SCI VL - 346 PY - 2024 PG - 12 SN - 0024-3205 DO - 10.1016/j.lfs.2024.122633 UR - https://m2.mtmt.hu/api/publication/34804165 ID - 34804165 N1 - Export Date: 22 April 2024; CODEN: LIFSA AB - Systemic administration of ammonium chloride (NH4Cl), an acidifying agent used in human patients and experimental conditions, causes hypothermia in mice, however, the mechanisms of the thermoregulatory response to NH4Cl and whether it develops in other species remained unknown.We studied body temperature (Tb) changes in rats and mice induced by intraperitoneal administration of NH4Cl after blockade of transient receptor potential vanilloid-1 (TRPV1) or ankyrin-1 (TRPA1) channels.In rats, NH4Cl decreased Tb by 0.4-0.8°C (p < 0.05). The NH4Cl-induced hypothermia also developed in Trpv1 knockout (Trpv1-/-) and wild-type (Trpv1+/+) mice, however, the Tb drop was exaggerated in Trpv1-/- mice compared to Trpv1+/+ controls with maximal decreases of 4.0 vs. 2.1°C, respectively (p < 0.05). Pharmacological blockade of TRPV1 channels with AMG 517 augmented the hypothermic response to NH4Cl in genetically unmodified mice and rats (p < 0.05 for both). In contrast, when NH4Cl was infused to mice genetically lacking the TRPA1 channel, the hypothermic response was significantly attenuated compared to wild-type controls with maximal mean Tb difference of 1.0°C between the genotypes (p = 0.008). Pretreatment of rats with a TRPA1 antagonist (A967079) also attenuated the NH4Cl-induced Tb drop with a maximal difference of 0.7°C between the pretreatment groups (p = 0.003).TRPV1 channels limit, whereas TRPA1 channels exaggerate the development of NH4Cl-induced hypothermia in rats and mice, but other mechanisms are also involved. Our results warrant for regular Tb control and careful consideration of NH4Cl treatment in patients with TRPA1 and TRPV1 channel dysfunctions. LA - English DB - MTMT ER - TY - JOUR AU - Szilágyi, O AU - Fekete, Kata AU - Pákai, Eszter AU - Bakos, R AU - Ungár Tamás Lászlóné Polyák, Éva AU - Garami, András TI - Természetes édesítőszerek hatásának vizsgálata JF - EGÉSZSÉG-AKADÉMIA J2 - EGÉSZSÉG-AKADÉMIA VL - 14 PY - 2023 IS - 1-2 SP - 12 EP - 22 PG - 11 SN - 2061-2850 UR - https://m2.mtmt.hu/api/publication/34448325 ID - 34448325 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Pintér, Erika AU - Garami, András AU - Szállási, Árpád TI - From capsaicin to TRPV1: The “hot” legacy of János Szolcsányi JF - TEMPERATURE J2 - TEMPERATURE VL - 10 PY - 2023 IS - 1 SP - 1 EP - 2 PG - 2 SN - 2332-8940 DO - 10.1080/23328940.2023.2194191 UR - https://m2.mtmt.hu/api/publication/33928122 ID - 33928122 N1 - Front Matter - Editorial LA - English DB - MTMT ER - TY - JOUR AU - Garami, András AU - Hegyi, Péter TI - Precision Medicine in Pancreatitis : The Future of Acute Pancreatitis Care JF - FUNCTION J2 - FUNCTION VL - 4 PY - 2023 IS - 3 PG - 8 SN - 2633-8823 DO - 10.1093/function/zqad015 UR - https://m2.mtmt.hu/api/publication/33813732 ID - 33813732 AB - Acute pancreatitis (AP) continues to present a substantial burden to patients and healthcare personnel. Despite its occasionally severe progression and high mortality rate, there is no specific therapy that could be routinely applied in patients with AP. Here, we review treatment possibilities in AP, describe how the treatment approaches have changed in pancreatic cancer as an analogy, and point out potential causes for the failure of clinical trials on AP. We highlight that instead of attempting to discover generalized treatment options that could be used in any AP patient, it is time for a paradigm shift in the treatment of AP, which would help to focus more on individual patients or specific patient subpopulations when designing clinical trials and therapeutic approaches (similarly as in pancreatic cancer). Since the recruitment of specific patient subpopulations with AP could take excessive time if clinical centers work separately, the development of precision medicine in AP would require to establish an expert committee, eg, Pancreatitis Precision Medicine Interest Group, which could organize and coordinate the activities of the joined centers. With the joined forces of expert clinicians and leading centers, a new era could start in the treatment of AP, in which personalized treatment options could be discovered and introduced to efficiently reduce the burden of the disease on patients and healthcare workers. LA - English DB - MTMT ER - TY - JOUR AU - Garami, András AU - Steiner, A.A. AU - Pákai, Eszter AU - Wanner, S.P. AU - Almeida, M.C. AU - Kéringer, Patrik AU - Oliveira, D.L. AU - Nakamura, K. AU - Morrison, S.F. AU - Romanovsky, A.A. TI - The neural pathway of the hyperthermic response to antagonists of the transient receptor potential vanilloid-1 channel JF - TEMPERATURE J2 - TEMPERATURE VL - 10 PY - 2023 IS - 1 SP - 136 EP - 154 PG - 19 SN - 2332-8940 DO - 10.1080/23328940.2023.2171671 UR - https://m2.mtmt.hu/api/publication/33756378 ID - 33756378 LA - English DB - MTMT ER - TY - JOUR AU - Válik, Angyalka AU - Harangozó, Katalin AU - Garami, András AU - Juhász, Zsolt AU - Józsa, Gergő AU - Lőrincz, Aba Tamás TI - Mid-Term Follow-Up Study of Children Undergoing Autologous Skin Transplantation for Burns JF - LIFE-BASEL J2 - LIFE-BASEL VL - 13 PY - 2023 IS - 3 PG - 12 SN - 2075-1729 DO - 10.3390/life13030762 UR - https://m2.mtmt.hu/api/publication/33728536 ID - 33728536 AB - Deep partial and full-thickness burns require surgical treatment with autologous skin grafts after necrectomy, which is the generally accepted way to achieve permanent wound coverage. This study sought to examine the grafted and donor areas of children who underwent autologous skin transplantation, using two assessment scales to determine the severity of the scarring and the cosmetic outcome during long-term follow-up. At the Surgical Unit of the Department of Paediatrics of the University of Pécs, between 1 January 2015 and 31 December 2019, children who had been admitted consecutively and received autologous skin transplantation were analyzed. Twenty patients met the inclusion criteria in this retrospective cohort study. The authors assessed the results using the Patient and Observer Scar Assessment Scale (POSAS) and the Vancouver Scar Scale (VSS). There was a significant difference in how parents and examiners perceived the children's scars. In the evaluation of the observer scale, the most critical variables for the area of skin grafted were relief and thickness. Besides color, relief was the worst clinical characteristic on the patient scale. However, when medical professionals evaluated the donor site, significantly better results were obtained compared to the transplanted area (average observer scale score: 1.4 and 2.35, p = 0.001; VSS: 0.85 vs. 2.60, p < 0.001), yet it was similar to the graft site in the parents' opinion (Patient Scale: 2.95 and 4.45, p = 0.181). LA - English DB - MTMT ER - TY - JOUR AU - Bakó, Eszter AU - Fehérvári, Péter AU - Garami, András AU - Dembrovszky, Fanni AU - Gunther, Emese Eszter AU - Hegyi, Péter AU - Csupor, Dezső AU - Böszörményi, Andrea TI - Efficacy of Topical Essential Oils in Musculoskeletal Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials JF - PHARMACEUTICALS J2 - PHARMACEUTICALS-BASE VL - 16 PY - 2023 IS - 2 PG - 15 SN - 1424-8247 DO - 10.3390/ph16020144 UR - https://m2.mtmt.hu/api/publication/33578785 ID - 33578785 AB - Essential oils (EOs) are widely used topically in musculoskeletal disorders (MSDs); however, their clinical efficacy is controversial. Our aim was to find evidence that topical EOs are beneficial as an add-on treatment in MSDs. We performed a systematic review and meta-analysis to summarize the evidence on the available data of randomized controlled trials (RCTs). The protocol of this work was registered on PROSPERO. We used Web of Science, EMBASE, PubMed, Central Cochrane Library and Scopus electronic databases for systematic search. Eight RCTs were included in the quantitative analysis. In conclusion, EO therapy had a favorable effect on pain intensity (primary outcome) compared to placebo. The greatest pain-relieving effect of EO therapy was calculated immediately after the intervention (MD of pain intensity = −0.87; p = 0.014). EO therapy had a slightly better analgesic effect than placebo one week after the intervention (MD of pain intensity = −0.58; p = 0.077) and at the four-week follow-up as well (MD of pain intensity = −0.52; p = 0.049). EO therapy had a beneficial effect on stiffness (a secondary outcome) compared to the no intervention group (MD = −0.77; p = 0.061). This systematic review and meta-analysis showed that topical EOs are beneficial as an add-on treatment in reducing pain and stiffness in the investigated MSDs. LA - English DB - MTMT ER - TY - JOUR AU - Toldi, János AU - Kelava, Leonardo AU - Márton, Sándor AU - Mühl, Diána AU - Kustán, Péter AU - Feher, Zsolt AU - Maár, Klaudia AU - Garai, János AU - Pákai, Eszter AU - Garami, András TI - Distinct patterns of serum and urine macrophage migration inhibitory factor kinetics predict death in sepsis : a prospective, observational clinical study JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 13 PY - 2023 IS - 1 PG - 15 SN - 2045-2322 DO - 10.1038/s41598-023-27506-6 UR - https://m2.mtmt.hu/api/publication/33564254 ID - 33564254 AB - Macrophage migration inhibitory factor (MIF) has been considered as a biomarker in sepsis, however the predictive value of the pattern of its kinetics in the serum and in the urine has remained unclarified. It is also unclear whether the kinetics of MIF are different between males and females. We conducted a single-center prospective, observational study with repeated measurements of MIF in serum and urine on days 0, 2, and 4 from admission to the intensive care unit (ICU) in 50 adult septic patients. We found that in patients who died within 90 days, there was an increase in serum MIF level from day 0 to 4, whereas in the survivors there was rather a decrease (p = 0.018). The kinetics were sex-dependent as the same difference in the pattern was present in males (p = 0.014), but not in females (p = 0.418). We also found that urine MIF was markedly lower in patients who died than in survivors of sepsis (p < 0.050). Urine MIF levels did not show temporal changes: there was no meaningful difference between day 0 and 4. These results suggest that kinetics of serum MIF during the initial days from ICU admission can predict death, especially in male patients. Additionally, lower urine MIF levels can also indicate death without showing meaningful temporal kinetics. LA - English DB - MTMT ER -